Support women in science at Burnet Institute
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
1991 (20)
December, 1991 (1)
- Cord whole blood hyperviscosity: measurement, definition, incidence and clinical features.
Drew JH, Guaran RL, Grauer S, Hobbs JB
J Paediatr Child Health. 1991 Dec; 27(6):363-365
November, 1991 (1)
- Lack of evidence of occult human immunodeficiency virus in seronegative individuals at very high risk of infection.
Crowe SM, Elbeik T, Ulrich PP, Mills J, Moss A
J Med Virol. 1991 Nov; 35(3):160-164
October, 1991 (3)
- Identification of four different CD46 (MCP) molecules with anti-peptide antibodies.
Purcell DF, Jonstone RW, McKenzie IF
Biochem Biophys Res Commun. 1991 Oct; 180(2):1091-1097 - Estimating the extent of underreporting in AIDS surveillance.
Gertig DM, Marion SA, Schechter MT
AIDS. 1991 Oct; 5(10):1157-1164 - N-terminal residues 105-117 of HIV-1 gp120 are not involved in CD4 binding.
el Ahmar W, Poumbourios P, McPhee DA, Kemp BE
AIDS Res Hum Retroviruses. 1991 Oct; 7(10):855-858
September, 1991 (3)
- Entry of human immunodeficiency virus infection into a population of injecting drug users, Victoria, 1990.
Crofts N, Hay M
Med J Aust. 1991 Sep; 155(6):378-382 - Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG.
Hulett MD, Osman N, McKenzie IF, Hogarth PM
J Immunol. 1991 Sep; 147(6):1863-1868 - The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive.
Fairley CK, Mijch A, Gust ID, Nichilson S, Dimitrakakis M, Lucas CR
Transplantation. 1991 Sep; 52(3):497-500
August, 1991 (1)
- Hepatitis C antibody testing: problems associated with non-specific binding.
Nicholson S, Leslie DE, Efandis T, Fairley CK, Gust ID
J Virol Methods. 1991 Aug; 33(3):311-317
July, 1991 (3)
- Public health control of HBV: worldwide HBV vaccination programme.
Gust I
Prog Clin Biol Res. 1991 Jul; 364:333-342 - Design of new anti-viral agents for chronic hepatitis B virus infection.
Locarnini S
J Gastroenterol Hepatol. 1991 Jul; 6 Suppl 1:18-22 - Hepatitis A virus and hepatitis A infection.
Ross BC, Anderson DA, Gust ID
Adv Virus Res. 1991 Jul; 39:209-253
June, 1991 (1)
- Antibodies to gp41 and nef in otherwise HIV-negative homosexual man with Kaposi's sarcoma.
Bowden FJ, McPhee DA, Deacon NJ, Cumming SA, Doherty RR, Sonza S, Lucas CR, Crowe SM
Lancet. 1991 Jun; 337(8753):1313-1314
May, 1991 (3)
- Direct quantification of HIV-1 infectivity for monocyte--macrophages using an infectious focus assay.
Sonza S, Burgess SH, Crowe SM
AIDS. 1991 May; 5(5):571-574 - Testing of saliva for antibodies to HIV-1.
Crofts N, Nicholson S, Coghlan P, Gust ID
AIDS. 1991 May; 5(5):561-563 - Characterization of hepatitis A virus capsid proteins with antisera raised to recombinant antigens.
Ross BC, Anderson DA
J Virol Methods. 1991 May; 32(2-3):213-220
April, 1991 (1)
- Rapid whole blood assay for HIV-1 seropositivity using an Fab-peptide conjugate.
Wilson KM, Gerometta M, Rylatt DB, Bundesen PG, McPhee DA, Hillyard CJ, Kemp BE
J Immunol Methods. 1991 Apr; 138(1):111-119
March, 1991 (1)
- Digoxigenin-labeled probes for the detection of hepatitis B virus DNA in serum.
Guo KJ, Bowden DS
J Clin Microbiol. 1991 Mar; 29(3):506-509
January, 1991 (2)
- Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons.
Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF
J Acquir Immune Defic Syndr. 1991 Jan; 4(8):770-776 - Mediators of fusion between HIV-infected macrophages and lymphoid cells.
Crowe S, Mills J, McGrath MS
Adv Exp Med Biol. 1991 Jan; 300:57-66; discussion 67
Year
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
- 1997
- 1996
- 1995
- 1994
- 1993
- 1992
- 1991
- 1990
- 1989
- 1988
- 1987
- 1982
- 1981
- 1955
Program
- All
- Executive (0)
- Healthy Mothers, Healthy Babies (HMHB) (0)
- Towards Eliminating HIV (0)
- Strategic Funding & Partnerships Executive Team (0)
- Disease Elimination (0)
- Maternal, Child and Adolescent Health (0)
- Philanthropy and Supporter Engagement (0)
- Health Security and Pandemic Preparedness (0)
- Eliminate Malaria (0)
- Eliminate Tuberculosis (TB) (0)
- Finance (0)
- Healthy Ageing (0)
- Human Resources (0)
- Burnet Honorary Research Fellows (0)
- Research Support and Facilities (0)
- Harm Reduction (0)
- Information Technology (0)
- Burnet Vaccine Initiative (0)
- Laboratory Services (0)
- Eliminate Viral Hepatitis (0)
- Education & Training (0)
- Infectious Diseases Elimination (0)
- Support Services Group (0)
- Project Management and Quality Assurance Office (0)
- Marketing and Communications (0)
- International Operations (0)
- Commercialisation, Innovation and Industry Partnerships (0)
Discipline
- All
- Life Sciences (0)
- Public Health (0)
- International Development (0)
Research Theme
- All
- HIV and AIDS (10)
- Immune Disease and Cancer (1)
- Hepatitis B (5)
- Hepatitis C (2)
- Injecting Drug Use (1)
